| Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients AM Riccio, RW Dal Negro, C Micheletto, L De Ferrari, C Folli, A Chiappori, ... International journal of immunopathology and pharmacology 25 (2), 475-484, 2012 | 149 | 2012 |
| Comprehensive effects of supplemented essential amino acids in patients with severe COPD and sarcopenia RW Dal Negro, R Aquilani, S Bertacco, F Boschi, C Micheletto, S Tognella Monaldi archives for chest disease 73 (1), 2010 | 96 | 2010 |
| Comorbidities, cardiovascular therapies, and COVID-19 mortality: a nationwide, Italian observational study (ItaliCO) F Polverino, DA Stern, G Ruocco, E Balestro, M Bassetti, M Candelli, ... Frontiers in cardiovascular medicine 7, 585866, 2020 | 85 | 2020 |
| Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial Inflammation R Dal Negro, C Micheletto, S Tognella, M Visconti, C Turati Advances in therapy 25, 1019-1030, 2008 | 80 | 2008 |
| Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues A Roggeri, C Micheletto, DP Roggeri International Journal of Chronic Obstructive Pulmonary Disease, 597-602, 2016 | 79 | 2016 |
| Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months AM Riccio, P Mauri, L De Ferrari, R Rossi, D Di Silvestre, L Benazzi, ... Clinical and translational allergy 7, 1-10, 2017 | 77 | 2017 |
| Salmeterol & Fluticasone 50 μg/250 μg bid in combination provides a better long-term control than salmeterol 50 μg bid alone and placebo in COPD patients already treated with … RW Dal Negro, C Pomari, S Tognella, C Micheletto Pulmonary pharmacology & therapeutics 16 (4), 241-246, 2003 | 76 | 2003 |
| Determinants of persistence of symptoms and impact on physical and mental wellbeing in Long COVID: A prospective cohort study E Righi, M Mirandola, F Mazzaferri, G Dossi, E Razzaboni, A Zaffagnini, ... Journal of Infection 84 (4), 566-572, 2022 | 73 | 2022 |
| Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD RW Dal Negro, M Visconti, C Micheletto, S Tognella Pulmonary pharmacology & therapeutics 21 (2), 304-308, 2008 | 69 | 2008 |
| Asthma in a large COVID-19 cohort: prevalence, features, and determinants of COVID-19 disease severity M Caminati, A Vultaggio, A Matucci, G Senna, F Almerigogna, ... Respiratory Medicine 176, 106261, 2021 | 62 | 2021 |
| Small airway dysfunction and bronchial asthma control: the state of the art M Cottini, C Lombardi, C Micheletto Asthma research and practice 1, 1-11, 2015 | 57 | 2015 |
| Asthmatic patients in COVID-19 outbreak: few cases despite many cases M Caminati, C Lombardi, C Micheletto, E Roca, B Bigni, F Furci, D Girelli, ... Journal of Allergy and Clinical Immunology 146 (3), 541-542, 2020 | 56 | 2020 |
| Prevalence of tracheobronchomalacia and excessive dynamic airway collapse in bronchial asthma of different severity RW Dal Negro, S Tognella, M Guerriero, C Micheletto Multidisciplinary Respiratory Medicine 8, 1-5, 2013 | 53 | 2013 |
| Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA‐sensitive asthmatics: a controlled study vs placebo C Micheletto, S Tognella, M Visconti, C Pomari, F Trevisan, RW Dal Negro Allergy 59 (3), 289-294, 2004 | 52 | 2004 |
| Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management M Caminati, B Olivieri, A Dama, C Micheletto, P Paggiaro, P Pinter, ... Expert Review of Respiratory Medicine 16 (7), 713-721, 2022 | 51 | 2022 |
| Severe asthma in adults does not significantly affect the outcome of COVID‐19 disease: results from the Italian Severe Asthma Registry L Antonicelli, C Tontini, G Manzotti, L Ronchi, A Vaghi, F Bini, ... Allergy 76 (3), 902, 2021 | 51 | 2021 |
| Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy RW Dal Negro, L Pradelli, S Tognella, C Micheletto, S Iannazzo European annals of allergy and clinical immunology 43 (2), 45, 2011 | 46 | 2011 |
| COVID‐19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. A Matucci, M Caminati, E Vivarelli, A Vianello, C Micheletto, F Menzella, ... Allergy 76 (3), 2021 | 45 | 2021 |
| Costs of asthma in Italy: results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study RW Dal Negro, C Micheletto, R Tosatto, M Dionisi, P Turco, CF Donner Respiratory medicine 101 (12), 2511-2519, 2007 | 42 | 2007 |
| Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience M Caminati, G Senna, G Stefanizzi, R Bellamoli, S Longhi, ... BMC Pulmonary Medicine 16, 1-9, 2016 | 41 | 2016 |
